Eupry Competitive Intelligence & Landscape
eupry.com ·
Overview
Eupry Overview
Eupry’s mission is to automate and digitalize temperature compliance processes, reducing waste of resources and time while enhancing safety and quality control in the distribution of critical healthcare products. The company employs over 60 staff members and has a global customer base of more than 1,000 clients, including major pharmaceutical companies like Novo Nordisk, AstraZeneca, and others (eupry.com, tracxn.com). Its value proposition centers on providing reliable, scalable, and user-friendly compliance solutions that improve operational efficiency and support global health initiatives, such as vaccine distribution during the COVID-19 pandemic (thehub.io).
Sources
Eupry
eupry.com
Eupry
thehub.io
Eupry - 2026 Company Profile & Team
tracxn.com
Eupry ApS
augustinusfabrikker.dk
One vendor, one solution, all you need for GxP compliance
eupry.com
Eupry Company Overview, Contact Details & Competitors | LeadIQ
leadiq.com
Eupry - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
tracxn.com
Eupry funding & investors
tracxn.com
Eupry Weekly Intel Updates
Receive weekly intel updates about Eupry straight to your inbox.
Competitors
Eupry Competitors
In terms of market positioning, Eupry is positioned as a scalable, user-friendly solution suitable for small to medium-sized enterprises, contrasting with larger, more feature-rich platforms like Crayon or Klue, which target enterprise clients with broader competitive intelligence needs (RivalSift). While Eupry’s pricing details are not explicitly listed, it is likely more affordable than high-end competitors, aligning with its focus on accessible, straightforward solutions for regulated industries. Its market share is growing steadily within niche sectors, driven by its compliance-centric features and ease of deployment.
Product & Pricing
Eupry Product and Pricing Intelligence
Regarding pricing, specific plans and tiers for Eupry are not explicitly detailed in the available search results. However, Eupry provides a free downloadable product catalog that includes technical specifications and solution options, indicating a tiered approach with different features and capabilities (eupry). The company emphasizes scalable, automated, and compliance-focused solutions, which suggests a range of offerings tailored to different customer needs, from basic monitoring to advanced, integrated systems.
Recent developments highlight Eupry’s significant funding, with a recent $24 million Series A round, supporting its growth and market expansion. Their solutions are designed to simplify manual processes, reduce errors, and ensure regulatory compliance, making them attractive for large-scale pharmaceutical and healthcare organizations seeking reliable temperature monitoring (leadiq). While detailed pricing plans and feature distinctions are not publicly listed, Eupry’s focus on compliance and automation positions it as a premium provider in the temperature monitoring market.
Sources
Automated temperature monitoring for GMP and GDP
eupry.com
Eupry Company Overview, Contact Details & Competitors | LeadIQ
leadiq.com
Pricing Plans for Competitor Price Monitoring | Pricefy
pricefy.io
Pricing Intelligence Software: Tools & Comparison | Pryse
pryse.ai
ATEK vs Eupry | Pharma Monitoring Comparison
atek.io
Ad Campaigns
Eupry Ad Campaigns
Eupry is currently running 2,704 ads across Google, LinkedIn — 2,000 on Google and 704 on LinkedIn. Explore Eupry's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.
See of Eupry's ads
Browse the live creative across Google, Meta & LinkedIn in the ad library
Hiring & Layoffs
Eupry Hiring and Layoffs
Regarding hiring trends, Eupry continues to expand its team, with recent job postings for roles such as Chief Technology Officer, Revenue Operations Analyst, and Customer Relation Specialist in Copenhagen, indicating ongoing recruitment to support its growth and innovation initiatives (Life Science Talent Hub). The company’s hiring pattern suggests a focus on strengthening its technological and operational capabilities to enhance its market leadership and product offerings. Notably, the company has not publicly reported layoffs, which aligns with its growth-oriented strategy and recent funding success, signaling a stable and expanding organizational structure (DailyRemote). Overall, Eupry’s hiring and funding patterns reflect a strategic focus on scaling operations, technological innovation, and market expansion.
Sources
Eupry secures over DKK 170 million in Series A funding | Kromann Reumert
kromannreumert.com
Eupry Company Overview, Contact Details & Competitors | LeadIQ
leadiq.com
Eupry Jobs in Nordic Life Science Startups - Life Science Talent Hub
talent-hub.life-science-talent-solutions.dk
Eupry ApS - Remote Work From Home Jobs & Careers
dailyremote.com
Eupry | Denmark’s Export & Investment Fund Job Board
jobs.eifo.dk
Eupry funding & investors
tracxn.com
Leadership
Eupry Management and Leadership Team
Sources
Eupry ApS | Chr. Augustinus Fabrikker
augustinusfabrikker.dk
Eupry Company Overview, Contact Details & Competitors | LeadIQ
leadiq.com
Louise Hartmann-Kruckow
theorg.com
The data loggers | Eupry
eupry.com
Eupry - The Hub
thehub.io
Eupry - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
tracxn.com
Financials
Eupry Financial Performance, Fundraising, M&A
In terms of fundraising, Eupry secured a significant Series A funding round of $24 million in December 2024, led by Chr. Augustinus Fabrikker, an investment firm associated with the Augustinus Foundation. This round also included participation from Ugly Duckling Ventures, EIFO, and Sagitta, highlighting strong investor confidence in its innovative temperature monitoring solutions (MergerLinks).
Regarding M&A activity, there are no publicly available records of acquisitions involving Eupry as of March 2026. The company's recent growth, funding, and revenue figures suggest a healthy financial position and a focus on expanding its market presence in the cold chain and temperature monitoring industry (Tracxn). Overall, Eupry appears to be a financially robust company with active investor backing and significant revenue growth.
Sources
How Eupry hit $7.2M revenue with a 65 person team in 2025. - Latka
getlatka.com
MergerLinks - Chr. Augustinus Fabrikker led a $24m Series A funding round in Eupry.
app.mergerlinks.com
Eupry Revenue and Competitors
growjo.com
Eupry funding & investors
tracxn.com
Eupry - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
tracxn.com
Partnerships
Eupry Partnerships, Clients and Vendors
In terms of enterprise clients, Eupry counts over 1,000 customers worldwide, including major pharmaceutical companies such as Novo Nordisk, AstraZeneca, and Agilent Technologies, as well as logistics giants like DHL and FedEx. These clients rely on Eupry's IoT temperature monitoring solutions for GxP compliance, calibration, and validation in regulated environments (Eupry, thehub.io).
Eupry’s ecosystem relationships extend to collaborations with research and development entities like DTU Vet and integration partners such as AWS, leveraging cloud-based platforms for scalable, compliant monitoring solutions. Their patented ALIIO calibration technology and cloud-native platform demonstrate a strategic focus on innovation and compliance, positioning Eupry as a key player within the pharma and biotech ecosystems (Compare Eupry).
Sources
One vendor, one solution, all you need for GxP compliance
eupry.com
Eupry - The Hub
thehub.io
Atos partners with Eupry to offer a Compliance Monitoring service for ...
atos.net
ATEK vs Eupry | Pharma Monitoring Comparison
atek.io
The data loggers | Eupry
eupry.com
View Profile: Eupry ApS
db.biochannelpartners.com
Eupry products
eupry.com
Eupry Partner Site
partner.eupry.com
Events
Eupry Event Participations
In addition to webinars, Eupry offers on-demand sessions, including a virtual launch of "Mastering Temperature Mapping" and discussions on AI in GxP, providing valuable insights into compliance practices (eupry.com). They also conduct specialized webinars like "How to eliminate the gaps in your temperature compliance process," aimed at helping organizations unify and optimize their monitoring, calibration, and mapping efforts (eupry.com).
While specific conferences and trade shows are not explicitly listed in the search results, Eupry’s engagement through these webinars and on-demand content indicates their active involvement in industry education and community building within the GxP compliance sector (eupry.com).
Frequently Asked Questions
What does Eupry's Series A composition — led by Chr. Augustinus Fabrikker with EIFO participation — signal about its strategic ownership direction?
Eupry's December 2024 Series A is effectively a strategic consolidation around its lead investor: Chr. Augustinus Fabrikker, the industrial holding company that already owns Eupry, led the $24 million round, with Louise Krogh Rindom — an Augustinus Fabrikker representative — installed as Chairman in 2024. EIFO's co-participation (Denmark's export and investment fund) signals that at least part of the round is tied to international expansion ambitions, consistent with the stated U.S. scale-up objective. This is less a classic venture round and more a controlled growth injection by a committed industrial owner, which reduces near-term M&A or IPO probability but provides patient capital for a multi-year U.S. push.
Is Eupry's $7.2M reported revenue consistent with its $31.7M estimated ARR, and what does the gap say about data reliability?
The two figures — $7.2M actual 2025 revenue (Latka) versus $31.7M estimated annual revenue (Growjo) — are irreconcilable at face value and should be treated with caution. Latka typically captures reported or survey-based SaaS ARR, while Growjo estimates are algorithmically derived and frequently overstated for private companies. The more defensible anchor is $7.2M for 2025 with 65 employees, implying roughly $110K revenue per employee — plausible for a compliance SaaS at this stage. Analysts should weight the lower figure and treat the $31.7M estimate as an outlier until audited figures become available.
What does Eupry's simultaneous hiring for a CTO, Revenue Operations Analyst, and Customer Relation Specialist suggest about where the business has gaps right now?
Hiring a CTO externally indicates Eupry either lacked or is upgrading technical leadership at the top, which is notable for a company that just closed a $24M round and is positioning ALIIO calibration technology as a core differentiator — it suggests the product roadmap is about to be significantly accelerated or restructured. The Revenue Operations hire points to a maturing go-to-market function moving beyond founder-led sales toward data-driven pipeline management, while the Customer Relation Specialist signals retention and expansion revenue (upsell within its 1,000+ customer base) is becoming a strategic priority alongside new logo acquisition.
What does Eupry's webinar calendar — including an 'How to Pass FDA Inspections' session — reveal about its U.S. go-to-market approach?
Eupry is using educational content around FDA inspection readiness as a top-of-funnel demand generation tool, which is a classic compliance-software playbook for entering the U.S. market without a large field sales force in place. Scheduling both an FDA-focused compliance webinar (March 19, 2026) and a product update webinar (March 31, 2026) in the same month suggests a deliberate sequence: attract regulated-industry prospects with regulatory pain, then convert them with a product pitch. This is consistent with a company that has Series A capital but is still building U.S. brand recognition and cannot yet rely on inbound referral volume.
How durable is the Atos partnership, and does it represent a real go-to-market channel or a COVID-era one-off?
The Atos partnership was announced in December 2020 specifically to address COVID-19 vaccine distribution logistics, which frames it as opportunistic rather than a structural channel agreement. There is no available evidence of the partnership being renewed, expanded, or producing ongoing joint deals beyond the vaccine rollout context. Given Atos's own significant corporate restructuring since 2022, treating this as an active channel would require fresh confirmation. Eupry's more durable enterprise relationships appear to be direct — with clients like Novo Nordisk, AstraZeneca, DHL, and FedEx — rather than routed through SI partners.
What does Eupry's customer list — Novo Nordisk, AstraZeneca, DHL, FedEx — tell us about its sales motion and deal concentration risk?
Landing Novo Nordisk, AstraZeneca, DHL, and FedEx as named clients with a 65-person team and approximately $7.2M revenue implies that these are likely smaller divisional or site-level deployments rather than enterprise-wide contracts, or that average contract values are modest relative to the logos. If revenue is concentrated among a handful of marquee accounts, Eupry carries meaningful churn risk from any single contract loss. Conversely, these relationships provide substantial expansion revenue potential if Eupry can roll out platform-wide across enterprise clients — a motion that the Revenue Operations hire and the U.S. scale-up suggest is now being formalized.
What does the AWS integration and cloud-native architecture signal about Eupry's defensibility against hardware-first competitors like Thermo Fisher?
Eupry's cloud-native architecture on AWS and its patented ALIIO on-the-wall calibration technology represent a deliberate bet that compliance buyers will prioritize software flexibility and reduced calibration labor over integrated hardware ecosystems. This positions Eupry as a disruptor against hardware-led incumbents like Thermo Fisher, which bundle monitoring with physical infrastructure. The defensibility lies in the ALIIO patent and the GxP-audit-ready data layer, which create switching costs once embedded in a customer's compliance workflow — but Eupry remains vulnerable to hardware vendors adding comparable software layers, particularly given Thermo Fisher's enterprise relationships and support infrastructure.
Is Eupry's 'over 1,000 customers' claim at $7.2M revenue a sign of a low-ACV, high-volume model, and what are the strategic implications?
At $7.2M across 1,000+ customers, blended ACV is at most $7,200 — consistent with a land-and-expand, site-license or per-sensor model targeting SMEs and individual facility managers rather than enterprise procurement. This is strategically coherent with Eupry's self-positioning as accessible and easy to deploy, but it creates a growth ceiling: reaching $30M+ revenue requires either significant ACV expansion into enterprise contracts, geographic multiplication of the same SME motion, or both. The U.S. expansion and the enterprise logos (Novo Nordisk, AstraZeneca) suggest Eupry is now consciously trying to shift up-market, which will test whether its product and sales motion can serve more complex enterprise procurement cycles.
What does Eupry's product webinar on AI in GxP compliance signal about its near-term product direction?
An on-demand AI-in-GxP webinar indicates Eupry is at minimum exploring — and publicly signaling — AI-augmented compliance features, likely targeting automated anomaly detection, predictive temperature excursion alerts, or AI-assisted audit trail generation. The fact that it is on-demand (not a live launch event) suggests this is still in an exploratory or early-feature stage rather than a full product release. For competitive analysts, this is a flag that Eupry is positioning to differentiate beyond sensor hardware and basic alerting, moving toward intelligent compliance decisioning — a space where larger players with more training data could also move quickly.
What does the absence of any M&A activity tell us about Eupry's current build-vs-buy posture?
With no recorded acquisitions as of March 2026, Eupry has deployed its $24M Series A entirely toward organic growth — headcount, market expansion, and product development. This is consistent with a company that is still scaling its core platform and does not yet have the operational bandwidth or integration infrastructure to absorb acquisitions. It also reflects the industrial-owner dynamic: Chr. Augustinus Fabrikker tends toward patient, organic value creation rather than aggressive roll-up strategies. A tuck-in acquisition becomes more plausible in a hypothetical Series B context if U.S. growth requires accelerated market entry or a capability (e.g., mapping software, logistics data integration) that would take too long to build.
How should a competitor interpret Eupry's focus on 'eliminating gaps' between monitoring, calibration, and mapping as a single platform play?
Eupry's messaging around unifying monitoring, calibration, and temperature mapping into one workflow is a direct attack on the fragmented multi-vendor setups that most regulated facilities currently run — different vendors for data loggers, calibration service providers, and mapping consultants. By collapsing these into one platform, Eupry increases switching costs significantly once all three workflows are live, and competes on total cost of compliance rather than point-solution pricing. Competitors that only offer one or two of these three capabilities should treat this bundling strategy as a threat to existing accounts where Eupry could displace a calibration or mapping incumbent even if the customer stays with a different primary monitoring vendor.
What does the stability of CEO Christian Elster Jacobsen alongside the external CTO search signal about Eupry's leadership evolution at this growth stage?
Jacobsen appears to have led Eupry since founding in 2014, providing continuity through the Series A and the U.S. expansion phase — a positive signal for investor alignment and product vision. The concurrent external CTO search suggests that technical leadership has been either founder-embedded or under-resourced relative to the engineering ambitions implied by the ALIIO patent, the AI-in-GxP initiative, and the cloud platform roadmap. Bringing in a dedicated CTO post-Series A is a standard professionalizing move, but it also introduces execution risk during the transition period, particularly if the incoming CTO resets engineering priorities or team structure in a company that is simultaneously accelerating U.S. market entry.
Powered by ForesightIQ · Competitive intelligence from digital exhaust